Vasculitis Trial, Recruiting NCT07244614 Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil Condition: Vasculitis
Back to Vasculitis

Vasculitis Trial, Recruiting

NCT07244614
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You do not object to taking part in the study
  • You are using a reliable form of contraception
  • You have been diagnosed with Behçet's disease according to the internationally recognised criteria (updated in 2013)
  • Your doctor has recommended ustekinumab or apremilast as part of your standard treatment for Behçet's syndrome affecting your skin and mucous membranes
  • If being considered for the ustekinumab group: You have active, recurring symptoms affecting your skin or mucous membranes (such as mouth ulcers, genital ulcers, skin lesions, or joint pain/inflammation) that have not responded to, or you could not tolerate, colchicine or apremilast
  • If being considered for the apremilast group: You have recurring active skin or mucous membrane symptoms from Behçet's syndrome and have not yet received any treatment for them
  • For mouth ulcers specifically: you have had two or more mouth ulcers in the month before joining the trial, and this has happened at least three times in the past 12 months, even after trying colchicine

Who may not be able to join:

  • You are currently pregnant
  • You have previously tried ustekinumab and it did not work for you
  • You have an active long-term infection (such as active tuberculosis, hepatitis B, or HIV) or an active cancer
  • You have received a live vaccine in the past 3 months
  • Your kidneys are not working well enough (confirm with trial site)
  • Your liver is not working well enough, based on blood test results (confirm with trial site)
  • Your blood counts are too low — this includes low platelets, low white blood cells, or low red blood cells/haemoglobin (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33142178042

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Groupe français d'étude des Maladies Inflammatoires de loeil
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
30 April 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Success at Week 24 will be defined as the absence of active mucocutaneous manifestations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov